Hippo pathway effectors are associated with glioma patient survival, control cell proliferation and sterol metabolism through TEAD3
Brain Pathology · 2025
DOI: 10.1111/bpa.70021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Pathology, 2025. Verfasst von Konstantin Masliantsev und 10 weiteren Autor:innen. Beteiligte Einrichtung: Université de Poitiers, CHU Poitiers, ProDiCeT, Poitiers, France. Hauptthemen laut MEDLINE: Transcription Factors, DNA-Binding Proteins, Brain Neoplasms, Protein Serine-Threonine Kinases. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ligue Contre le Cancer, Fonds Aliénor CHU Poitiers.
Abstract (Originalsprache)
Glioblastomas represent the most common and lethal primary brain tumors in the world. Despite therapeutic advances during the last two decades, patient prognosis remains very poor. The Hippo signaling pathway effectors YAP/TAZ‐TEADs play a crucial role in tumor progression and represent promising therapeutic targets in gliomas. In this study, we identified and investigated the clinical and biological significance of TEAD transcription factors. Through comprehensive analyses of TCGA glioma data and patient samples, we identified TEAD3‐4 transcription factors as robust prognostic markers of patient outcome. Using up to five different patient‐derived glioblastoma stem cell cultures, we confirmed the preferential expression and activation of TEAD3‐4 along with their transcriptional coactivators YAP/TAZ. Pharmacological inhibition of YAP/TAZ‐TEAD interaction by Verteporfin significantly decreased tumor cell growth, whereas specific inhibition of TEAD3 did not impact cell proliferation but affected sterol/cholesterol biosynthetic and metabolic processes. This study contributes to a better understanding of the role of Hippo effectors in glioblastoma pathophysiology. These transcription factors, particularly TEAD3, could potentially serve as therapeutic targets, especially considering recent data on cholesterol homeostasis in glioblastomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Poitiers, CHU Poitiers, ProDiCeT, Poitiers, France.
- CHU Poitiers, Laboratoire de Cancérologie Biologique, Poitiers, France.
- MGX-Montpellier GenomiX, Université de Montpellier, CNRS, INSERM, Montpellier, France.
- CHU Poitiers, Service d'Anatomie et de Cytologie Pathologiques, Poitiers, France.
- CHU Poitiers, Service de Neurochirurgie, Poitiers, France.
ORCID-Profile: Konstantin Masliantsev, Amandine Desette, Anaïs Noblanc, Pierre-Olivier Guichet
Förderung
- Ligue Contre le Cancer
- Fonds Aliénor CHU Poitiers
Zitieren
APA
Masliantsev, K., Desette, A., Gonzalez, A. A., Garrouche, I., Noblanc, A., Soulard, M., Triquard, M., Milin, S., Wager, M., Karayan-Tapon, L., & Guichet, P. O. (2025). Hippo pathway effectors are associated with glioma patient survival, control cell proliferation and sterol metabolism through TEAD3. Brain Pathology. https://doi.org/10.1111/bpa.70021
Vancouver
Masliantsev K, Desette A, Gonzalez AA, Garrouche I, Noblanc A, Soulard M, et al. Hippo pathway effectors are associated with glioma patient survival, control cell proliferation and sterol metabolism through TEAD3. Brain Pathology. 2025. doi:10.1111/bpa.70021
BibTeX
@article{Masliantsev2025,
author = {Masliantsev, Konstantin and Desette, Amandine and Gonzalez, Anne-Alicia and Garrouche, Inès and Noblanc, Anaïs and Soulard, Maleaume and Triquard, Mathis and Milin, Serge and Wager, Michel and Karayan-Tapon, Lucie and Guichet, Pierre-Olivier},
title = {Hippo pathway effectors are associated with glioma patient survival, control cell proliferation and sterol metabolism through TEAD3},
journal = {Brain Pathology},
year = {2025},
doi = {10.1111/bpa.70021}
}
EUVIMED